iRhythm

iRhythm has emerged from its regulatory purgatory as one of medtech's cleanest reacceleration stories: Q1 2026 revenue of $199.4M grew 25.7% year over year with gross margin at 70.9%, adjusted EBITDA turned meaningfully positive at $14.1M, guidance was raised to $875–885M (17–18% growth) with adjusted EBITDA margin lifted to 12–13%, and the stock jumped roughly 7% on the print. The franchise beneath those numbers is a category-defining machine: the Zio patch owns long-term ambulatory ECG the way Kleenex owns tissue, with FDA-cleared deep-learning analytics trained on millions of patient recordings — a data moat no competitor can synthesize — and management reports 93% of US covered lives now have access to Zio, the payer-coverage endgame that took a decade to assemble. Growth is broad-based across cardiology, primary care, innovative channels, and international, meaning the business is no longer a single-channel story, and the compliance chapter that terrified investors is resolved: the FDA warning letter from 2023 was answered with 510(k) clearances for the Zio AT updates, demonstrating the quality system can satisfy regulators under scrutiny. The forward catalysts stack up: a next-generation Zio algorithm is coming, primary-care expansion multiplies the prescriber base beyond cardiology's capacity constraints, and international remains early. Structurally, iRhythm sits on the right side of medicine's biggest current: AI-assisted diagnostics with a reimbursed, recurring, service-based revenue model — each disposable patch generating a billable analysis — in arrhythmia detection, where earlier AFib diagnosis demonstrably prevents strokes. As adjusted profitability scales against a fixed algorithmic cost base, the operating-leverage story that bulls always promised is finally, visibly arriving in the numbers.

iRhythm is a single-product company whose economics sit at the discretion of regulators, payers, and the Department of Justice — and all three have already demonstrated their power over it. The DOJ's Consumer Protection Branch subpoenaed the company in April 2023 in an investigation analysts tie to Zio AT — the same device whose marketing the FDA's May 2023 warning letter called out for overstating "near real-time monitoring" and use in high-risk patients, alongside findings that two patient deaths were not reported within required windows; the civil-fraud exposure from that combination remains an unquantified tail risk. Reimbursement concentration is the deeper structural flaw: essentially every Zio unit monetizes through a handful of billing codes, and the company's own history — the 2021 Medicare rate-setting episode, when a contractor's drastic price cut collapsed the stock — proves a single administrative decision can vaporize the P&L; "93% covered lives" is simultaneously the bull case and the ceiling, since coverage can now only erode. Competition is intensifying across every vector: Philips (BioTel) and Boston Scientific (Preventice) bundle cardiac monitoring into system-wide hospital relationships, cheaper patch entrants attack price, and consumer devices — Apple Watch, KardiaMobile — increasingly perform the first-line AFib screen that feeds iRhythm's funnel, threatening long-term disintermediation of low-acuity volume. The company still posted a $13.9M GAAP net loss in its best quarter ever, twenty years after founding, because the model carries a heavy human layer — technician review, logistics, billing — beneath the AI narrative. And at the premium multiple a 25%-growth medtech commands, the stock embeds flawless execution on next-gen product cycles while litigation, rate resets, and channel shifts each carry binary downside. Concentrated regulatory risk plus single-franchise dependence is exactly the profile that produces air pockets.